Select Language:
Hasten Biopharmaceutical has built a comprehensive commercial network across Southeast Asia, Australia, and South Korea, and has completed the transfer of market approvals for 70 products throughout Asia-Pacific markets.
Following its acquisition of regional rights to a portfolio of branded products in eight Asia-Pacific countries last June, and its initial product launch in April, the Hefei-based company announced on November 4 that its new infrastructure now covers key markets including South Korea, Thailand, Malaysia, Singapore, and Hong Kong.
The company has achieved significant success in Thailand, where its antihypertensive medication Edarbi ranks first in the angiotensin receptor blocker market. Its hypertension treatment Madiplot leads the third-generation calcium channel blocker segment, and its diabetes drug Oseni is the top seller in the dipeptidyl peptidase-4 inhibitor combination market.
“Global expansion presents complex challenges for emerging companies like ours,” said the CEO. “We’re transitioning from initial breakthroughs to establishing a sustainable healthcare ecosystem across the Asia-Pacific that offers operational globalization solutions for Chinese pharmaceutical companies.”
” Southeast Asia offers promising growth potential, driven by its population of 600 million and increasing rates of chronic disease,” remarked Peggy Fung, executive vice president and head of Asia-Pacific commercial operations. The company has partnered with Switzerland’s DKSH Group to utilize its regional regulatory and commercial expertise.
Establishing this commercial network marks a major milestone in the overseas expansion of Chinese pharma companies. As competition intensifies domestically, more manufacturers are expected to follow suit by building multinational operations.
Founded in 2020, the company operates a unified platform that encompasses research, development, manufacturing, and marketing. Its goal is to accelerate access to innovative medicines across the Asia-Pacific through a “global operation + local execution” approach.
ChatGPT
Perplexity
Gemini AI
Grok AI
